<DOC>
	<DOCNO>NCT00643747</DOCNO>
	<brief_summary>The purpose study determine whether gene therapy safe effective treatment severe childhood blindness cause mutation RPE65 .</brief_summary>
	<brief_title>Safety Study RPE65 Gene Therapy Treat Leber Congenital Amaurosis</brief_title>
	<detailed_description>The main objective propose trial determine safety efficacy subretinal administration recombinant adeno-associated viral vector ( rAAV 2/2.hRPE65p.hRPE65 ) three different dosage level individual autosomal recessive severe early-onset retinal degeneration due mutation RPE65 . We comprehensive clinical monitoring plan investigate safety efficacy vector delivery .</detailed_description>
	<mesh_term>Retinal Degeneration</mesh_term>
	<mesh_term>Leber Congenital Amaurosis</mesh_term>
	<criteria>Clinical diagnosis severe earlyonset retinal dystrophy confirm missense mutation ( ) RPE65 Visual acuity study eye well 6/36 Snellen Hypertension Diabetes mellitus Tuberculosis Renal impairment Immunocompromise Osteoporosis Gastric ulceration Severe affective disorder ) Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>retinal dystrophy</keyword>
	<keyword>Leber congenital amaurosis</keyword>
	<keyword>RPE65</keyword>
	<keyword>gene therapy</keyword>
</DOC>